IPS e.max is one of the most thoroughly evaluated ceramic systems available: more than 230 million restorations have been placed worldwide as of December 2024, and clinical data on this ceramic family spans 16 years. The portfolio includes lithium disilicate (IPS e.max Press and IPS e.max CAD), high-strength zirconia (IPS e.max ZirCAD) and a fluorapatite layering ceramic (IPS e.max Ceram). Whether for single-tooth restorations, bridges or implant-supported solutions, the materials enable aesthetic, long-lasting and customised treatment approaches in both analogue and digital workflows.

Clinical evidence builds confidence

The report documents notably high survival rates:

• 96.5% for IPS e.max Press over 16.9 years;
• 97.2% for IPS e.max CAD over ten years; and
• 99.0% for IPS e.max ZirCAD over five years.

This robust evidence allows for predictable treatment planning, reduces the need for retreatment, and fosters trust between dental practices, patients and dental laboratories. The report provides an evidence-based foundation for informed decision-making and is intended to support practices and laboratories in selecting materials with clinically proven quality and long-term reliability for their patients.

Volume 4 of the IPS e.max Scientific Report can be obtained through the company’s website.

Tags: